An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510995-18-00

Acronym

IDE397-001

Enrollment

Registered

2024-03-21

Start date

2023-03-01

Completion date

Unknown

Last updated

2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026